Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
National Psoriasis Foundation clinical consensus on disease severity.
Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ; National Psoriasis Foundation. Pariser DM, et al. Among authors: bagel j. Arch Dermatol. 2007 Feb;143(2):239-42. doi: 10.1001/archderm.143.2.239. Arch Dermatol. 2007. PMID: 17310004
PARTICIPANTS: This volunteer task force, led by David M. Pariser, MD, included Jerry Bagel, MD, Joel M. Gelfand, MD, MSCE, Neil J. Korman, MD, PhD, Christopher T. Ritchlin, MD, Bruce E. ...Pariser, MD, a statement was drafted by Elizabeth J. Horn, PhD, presen …
PARTICIPANTS: This volunteer task force, led by David M. Pariser, MD, included Jerry Bagel, MD, Joel M. Gelfand, MD, MSCE, Neil J …
Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
Bagel J, Novak K, Nelson E. Bagel J, et al. J Drugs Dermatol. 2023 Aug 1;22(8):766-772. doi: 10.36849/jdd.6830. J Drugs Dermatol. 2023. PMID: 37556520 Clinical Trial.
CONCLUSION: Tildrakizumab plus topical halcinonide ointment is safe and effective in controlling psoriasis for patients inadequately responding to tildrakizumab monotherapy.Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointme …
CONCLUSION: Tildrakizumab plus topical halcinonide ointment is safe and effective in controlling psoriasis for patients inadequately respond …
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. Lebwohl M, et al. Among authors: bagel j. J Am Acad Dermatol. 2008 Jan;58(1):94-105. doi: 10.1016/j.jaad.2007.08.030. Epub 2007 Nov 5. J Am Acad Dermatol. 2008. PMID: 17980456
Optimizing topical therapies for treating psoriasis: a consensus conference.
Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E; Psoriasis Process of Care Consensus Panel. Zeichner JA, et al. Among authors: bagel j. Cutis. 2010 Sep;86(3 Suppl):5-31; quiz 32. Cutis. 2010. PMID: 21049712
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J. Leonardi C, et al. Among authors: bagel j. Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20. Arch Dermatol. 2011. PMID: 21173304 Clinical Trial.
Consensus guidelines for the management of plaque psoriasis.
Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Hsu S, et al. Among authors: bagel j. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410. Arch Dermatol. 2012. PMID: 22250239
140 results